The National Institute for Health and Care Excellence (NICE) recommends that Tecentriq in combination with carboplatin and etoposide should not be made available for untreated extensive-stage Small Cell Lung Cancer in adults.- Genentech/Roche
Related news and insights
Merck announced the company is voluntarily withdrawing the U.S. indication for Keytruda (pembrolizumab) for the treatment of patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
In 2018, Opdivo (nivolumab) from BMS was granted accelerated approval by the FDA for the treatment of patients with small cell lung cancer (SCLC) whose disease has progressed after platinum-based chemotherapy and at least one other line of therapy.
Jazz Pharmaceuticals plc along with its partner, PharmaMar announced results from the ATLANTIS Phase III multicenter, randomized, controlled study evaluating Zepzelca (lurbinectedin) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine (CAV) for adult patients with small cell lung cancer (SCLC) whose disease progressed following one prior platinum-containing line.